Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| CP Circle Pharma, Inc.Company profile Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages. Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages. | $92.5M | Series ESeries C+ | Biotech | United States | Investors | |
| A AitiologicCompany profile A precision-medicine company developing liquid-biopsy tests that interpret cell-free DNA signals for early disease risk assessment. A precision-medicine company developing liquid-biopsy tests that interpret cell-free DNA signals for early disease risk assessment. | €6.4M | Seed | Biotech | Austria | Investors | |
| RI RegCell, Inc.Company profile RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development. RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development. | $44M | Series A | Biotech | United States | Investors | |
| RI ReEmerge, Inc.Company profile ReEmerge is developing Cognitive Network Restoration Therapy (CNRT) for people with chronic cognitive impairment after brain injury. The treatment targets underactive but viable neural circuits in the central thalamus to restore function across disrupted brain networks; the company is advancing this restorative approach through clinical development. ReEmerge is developing Cognitive Network Restoration Therapy (CNRT) for people with chronic cognitive impairment after brain injury. The treatment targets underactive but viable neural circuits in the central thalamus to restore function across disrupted brain networks; the company is advancing this restorative approach through clinical development. | $37M | Series A | Biotech, Healthtech | United States | Investors | |
| E EvvyCompany profile Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health. Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health. | $40M | Series B | Biotech, Healthtech | United States | Investors | |
| AB AOI Biosciences, Inc.Company profile A biotechnology company developing antibody diagnostics and drug-discovery methods for difficult protein targets. A biotechnology company developing antibody diagnostics and drug-discovery methods for difficult protein targets. | Undisclosed | Equity issuance and secondary transferUndisclosed | Biotech | Japan | Investors | |
| FL Ferm LabsCompany profile Ferm Labs develops fermentation-based flavour ingredients for food manufacturers, using fermentation science to deepen savoury taste and help reformulate products with less salt and fewer additives. Ferm Labs develops fermentation-based flavour ingredients for food manufacturers, using fermentation science to deepen savoury taste and help reformulate products with less salt and fewer additives. | €3M | Seed | Biotech, Foodtech | Switzerland | Investors | |
| SB Shennon BiotechnologiesCompany profile Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors. Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors. | $12M | FundingUndisclosed | Biotech | United States | Investors | |
| AB Athernal BioCompany profile Targeted immunotherapies aim to stop blood cancers by treating high-risk clonal hematopoiesis before malignancy emerges. Targeted immunotherapies aim to stop blood cancers by treating high-risk clonal hematopoiesis before malignancy emerges. | ~£700K | GrantUndisclosed | Biotech | United Kingdom | Investors | |
| E EthrisCompany profile Ethris develops inhaled mRNA therapeutics and vaccines for respiratory diseases, using proprietary RNA stabilization and nanoparticle delivery platforms. Ethris develops inhaled mRNA therapeutics and vaccines for respiratory diseases, using proprietary RNA stabilization and nanoparticle delivery platforms. | €30M | HERA Invest financingUndisclosed | Biotech | Germany | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.